Pages that link to "Q50973738"

The following pages link to The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen (Q50973738):

Displaying 28 items.

• Cytotoxic T cell immunity against telomerase reverse transcriptase in humans (Q24676613) (← links)
• Cancer gene and immunotherapy: recent developments (Q33717186) (← links)
• Transgenic expression of P1A induced thymic tumor: a role for onco-fetal antigens in tumorigenesis (Q33728430) (← links)
• Cancer therapy: new concepts on active immunization (Q33757797) (← links)
• Targeting pediatric malignancies for T cell-mediated immune responses (Q34108113) (← links)
• Specific immunotherapy of cancer in elderly patients (Q34400632) (← links)
• Stimulation of anti-tumor immunity by photodynamic therapy (Q34697795) (← links)
• Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. (Q35005912) (← links)
• Immunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option? (Q35142329) (← links)
• Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo. (Q36367821) (← links)
• De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. (Q36459332) (← links)
• Epitope Hierarchy of Spontaneous CD4+ T Cell Responses to LAGE-1 (Q37513115) (← links)
• The development and functions of CD4(+) T cells expressing a transgenic TCR specific for an MHC-I-restricted tumor antigenic epitope (Q37728225) (← links)
• Advances in Cellular Therapy for the Treatment of Thyroid Cancer (Q37776660) (← links)
• Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking (Q38288055) (← links)
• Limited expression of cancer-testis antigens in renal cell carcinoma patients (Q38292778) (← links)
• Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer and in healthy donors (Q40738048) (← links)
• Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. (Q40741662) (← links)
• Codon-Optimized P1A-Encoding DNA Vaccine: Toward a Therapeutic Vaccination against P815 Mastocytoma (Q41191220) (← links)
• The site of administration influences both the type and the magnitude of the immune response induced by DNA vaccine electroporation (Q41226107) (← links)
• T cell defined tumor antigens (Q41642406) (← links)
• Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A. (Q42134929) (← links)
• Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene (Q45746813) (← links)
• T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice. (Q45873576) (← links)
• Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver (Q47993681) (← links)
• Trap1a is an X-linked and cell-intrinsic regulator of thymocyte development. (Q54200911) (← links)
• Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma (Q57794659) (← links)
• The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection (Q77714923) (← links)